← Back to the full Peptide Guide overview
Important Disclaimer — Read Before Using This Page
This information is not intended for use by unlicensed individuals or by licensed professionals who lack adequate training and experience in assessing patients for peptide or hormone therapy. All clinical decisions and dosing must be made in consultation with a licensed, experienced physician and a licensed, experienced compounding pharmacist, and should be supported by published clinical studies.
The information presented here has been compiled using Artificial Intelligence, statements from videos and websites by apparent qualified professionals, and available published research. We strongly encourage exhaustive independent research before considering any therapy. Anyone starting a medication they have never taken before should take an extremely conservative approach.
Nothing on this page or in these videos should be taken as medical advice. These materials are provided only to help begin your research. All dosing and treatment decisions should be made between you and your medical providers after proper evaluation. We are not affiliated with any of the doctors whose videos appear on this page.
Tesamorelin FDA-Approved Off-Label for Visceral Fat
Brand: Egrifta
Category: GHRH Analog — Visceral Fat Reduction
How it works. Tesamorelin is a stabilized GHRH analog. Like sermorelin, it stimulates the pituitary to release growth hormone, which raises IGF-1 and drives downstream effects on fat metabolism. What sets tesamorelin apart is that it specifically targets visceral adipose tissue (VAT)—the dangerous fat that wraps around abdominal organs and drives insulin resistance, inflammation, and cardiovascular risk—without meaningfully reducing subcutaneous fat.
Why a physician prescribes it. Tesamorelin is FDA-approved as Egrifta for reduction of excess abdominal fat in HIV-associated lipodystrophy. That is the only approved indication. Off-label use for non-HIV visceral adiposity, metabolic syndrome, or cardiometabolic risk reduction requires a documented clinical rationale in the chart. The prescription is more defensible when the target is objectively measurable—elevated waist circumference, imaging-documented visceral fat, or measurable liver fat—rather than "patient wants a smaller belly." Because it has a real FDA-approved label and a known Phase 3 safety profile, tesamorelin sits on stronger regulatory ground than most other GH-axis peptides.
What to know before starting. Contraindications include active malignancy, pituitary disease, and pregnancy. Cautions include glucose intolerance, diabetes risk, edema, and joint pain. The most common side effects in the pivotal HIV trials were injection-site erythema and pruritus, rash, and flushing. IGF-1 elevation is expected and needs to be monitored so it does not exceed age-appropriate reference ranges. Patients expecting dramatic scale weight loss may be disappointed—tesamorelin can quietly shrink dangerous internal fat while the bathroom scale barely moves. Your prescriber should explain this distinction before you start.
Recommended Videos
Dr. Ashley Froese — This Is Not Covered — Dr Amazed: Tesamorelin DECIMATES Visceral Fat and MORE
Regan Archibald — What Is Tesamorelin Peptide
The Hunter Williams Podcast — The Tesamorelin Masterclass | Complete Researcher’s Guide (2026)
Video Sources & Independence
The videos linked on this page are provided solely for educational purposes. None of the physicians or channels featured are sponsored by, affiliated with, or compensated by NJ Weight Loss & Preventive Care Clinics, its physicians, or any individuals associated with our practice. We have selected these videos because they offer thoughtful, evidence-based discussion of mechanisms and clinical considerations. Viewers should evaluate all sources independently.
← Back to the full Peptide Guide overview · Peptide Dosing Reference →